JP2022511509A - 神経障害および神経障害の処置方法 - Google Patents

神経障害および神経障害の処置方法 Download PDF

Info

Publication number
JP2022511509A
JP2022511509A JP2021531942A JP2021531942A JP2022511509A JP 2022511509 A JP2022511509 A JP 2022511509A JP 2021531942 A JP2021531942 A JP 2021531942A JP 2021531942 A JP2021531942 A JP 2021531942A JP 2022511509 A JP2022511509 A JP 2022511509A
Authority
JP
Japan
Prior art keywords
patient
disorder
compound
disorders
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021531942A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511509A5 (https=
Inventor
キャボット ホプキンス，セス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of JP2022511509A publication Critical patent/JP2022511509A/ja
Publication of JP2022511509A5 publication Critical patent/JP2022511509A5/ja
Priority to JP2024199397A priority Critical patent/JP2025024102A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021531942A 2018-12-06 2019-12-05 神経障害および神経障害の処置方法 Pending JP2022511509A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024199397A JP2025024102A (ja) 2018-12-06 2024-11-15 神経障害および神経障害の処置方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862776247P 2018-12-06 2018-12-06
US62/776,247 2018-12-06
US201962829796P 2019-04-05 2019-04-05
US62/829,796 2019-04-05
PCT/US2019/064646 WO2020118032A1 (en) 2018-12-06 2019-12-05 Methods of treating neurological and psychiatric disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024199397A Division JP2025024102A (ja) 2018-12-06 2024-11-15 神経障害および神経障害の処置方法

Publications (2)

Publication Number Publication Date
JP2022511509A true JP2022511509A (ja) 2022-01-31
JP2022511509A5 JP2022511509A5 (https=) 2022-12-12

Family

ID=69024675

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021531942A Pending JP2022511509A (ja) 2018-12-06 2019-12-05 神経障害および神経障害の処置方法
JP2024199397A Pending JP2025024102A (ja) 2018-12-06 2024-11-15 神経障害および神経障害の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024199397A Pending JP2025024102A (ja) 2018-12-06 2024-11-15 神経障害および神経障害の処置方法

Country Status (9)

Country Link
US (3) US20200179336A1 (https=)
EP (1) EP3890726A1 (https=)
JP (2) JP2022511509A (https=)
KR (1) KR20210100667A (https=)
CN (2) CN118576586A (https=)
AU (2) AU2019394956B2 (https=)
CA (1) CA3122261A1 (https=)
MX (1) MX2021006553A (https=)
WO (1) WO2020118032A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201510665WA (en) 2009-12-04 2016-01-28 Sunovion Pharmaceuticals Inc Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders
MA45795A (fr) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
MX390141B (es) 2017-02-16 2025-03-20 Sunovion Pharmaceuticals Inc Metodos para tratar esquizofrenia
CA3070993C (en) 2017-08-02 2025-05-20 Sunovion Pharmaceuticals Inc. ISOCHROMANE COMPOUNDS AND THEIR USES
UA130249C2 (uk) 2018-02-16 2025-12-31 Сумітомо Фарма Америка, Інк. Солі, кристалічні форми і способи їх отримання
CA3180115A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
US20220165391A1 (en) * 2020-11-25 2022-05-26 Kyndryl, Inc. Multi-stage treatment recommendations
AU2022348905A1 (en) 2021-09-23 2024-04-11 Sumitomo Pharma America, Inc. Methods of treating metabolic disorders
CA3260160A1 (en) 2022-08-30 2024-03-07 Sumitomo Pharma America, Inc. ULOTARONT FOR THE ADJUVANT TREATMENT OF MAJOR DEPRESSIVE DISORDER
AU2023358704A1 (en) 2022-10-13 2025-05-29 Sumitomo Pharma America, Inc. Methods of reducing physical dependence to neuropsychiatric treatments
KR20250088777A (ko) 2022-10-28 2025-06-17 스미토모 파마 아메리카, 인크. 불안 및 연관된 상태를 치료하기 위한 울로타론트
WO2024107681A1 (en) 2022-11-15 2024-05-23 Sumitomo Pharma America, Inc. Methods of switching neuropsychiatric medications using ulotaront
CN115754079B (zh) * 2022-11-28 2025-04-04 合肥和合医疗科技有限公司 一种同时检测7种精神药物及其代谢产物含量的方法
CN117594119B (zh) * 2024-01-17 2024-05-10 北京大学第六医院 用于预测帕罗西汀或其药用盐对抑郁或焦虑症患者疗效的装置
WO2025252814A1 (en) 2024-06-04 2025-12-11 Duc Duy Vo Methods for treating trace amine-associated receptor 1 (taar1)-associated diseases or disorders comprising administration of novel taar1 agonists or pharmaceutical compositions thereof
WO2026015878A1 (en) * 2024-07-12 2026-01-15 Mindx Therapeutics, Inc. A new combination therapy for treatment-resistant depression in patients with co-morbid metabolic syndrome

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018151861A1 (en) * 2017-02-16 2018-08-23 Sunovion Pharamaceuticials Inc. Methods of treating schizophrenia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201510665WA (en) 2009-12-04 2016-01-28 Sunovion Pharmaceuticals Inc Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders
UA130249C2 (uk) 2018-02-16 2025-12-31 Сумітомо Фарма Америка, Інк. Солі, кристалічні форми і способи їх отримання
JP2021513972A (ja) * 2018-02-16 2021-06-03 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 社会的機能障害の治療方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018151861A1 (en) * 2017-02-16 2018-08-23 Sunovion Pharamaceuticials Inc. Methods of treating schizophrenia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NEUROPSYCHOPHARMACOLOGY, vol. VOL:41, NR:SUPPL. 1, JPN5022003507, December 2016 (2016-12-01), pages 222 - 1, ISSN: 0005370098 *
日薬理誌, vol. 128, JPN6023048255, 2006, pages 173 - 176, ISSN: 0005370099 *

Also Published As

Publication number Publication date
AU2025213591A1 (en) 2025-08-21
AU2019394956A1 (en) 2021-06-17
KR20210100667A (ko) 2021-08-17
CA3122261A1 (en) 2020-06-11
US20240350453A1 (en) 2024-10-24
US20250312308A1 (en) 2025-10-09
WO2020118032A1 (en) 2020-06-11
MX2021006553A (es) 2021-09-08
US20200179336A1 (en) 2020-06-11
JP2025024102A (ja) 2025-02-19
EP3890726A1 (en) 2021-10-13
CN118576586A (zh) 2024-09-03
AU2019394956B2 (en) 2025-05-08
CN113271936A (zh) 2021-08-17

Similar Documents

Publication Publication Date Title
JP2022511509A (ja) 神経障害および神経障害の処置方法
US11738002B2 (en) Methods of treating neurological and psychiatric disorders
AU2018201060B2 (en) 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
CN114340670B (zh) T-型钙通道调节剂的制剂及其使用方法
CN1206996C (zh) 用于治疗或预防睡眠障碍的药物组合物
CN115776894A (zh) T型钙通道调节剂的使用方法
JP2022535893A (ja) 放出調節製剤およびその使用
JP2009500420A (ja) エスゾピクロン及びｏ−デスメチルベンラファキシンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
JP2022535894A (ja) 放出調節製剤およびその使用
CA2590838A1 (en) Preventive or therapeutic agent for sleep disorder
JP3509637B2 (ja) 睡眠障害予防治療剤
JP7709202B2 (ja) 睡眠障害を伴うｃｎｓ障害の治療
HK40057761A (en) Methods of treating neurological and psychiatric disorders
JP2022087834A (ja) 放出調節製剤およびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240319

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240716